HAUPPAUGE, N.Y., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment ...
Acquisition will expand commercial presence and market opportunity in Brazil MEDFORD, N.Y., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care ...
A manufacturer of rapid diagnostic tests in Hauppauge has paid $500,000 to end an investigation by the U.S. Securities and Exchange Commission, according to a securities filing. Chembio Diagnostics ...
HAUPPAUGE, N.Y., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the CE mark for ...
HAUPPAUGE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today reported that, in ...
STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has ...
Chembio Diagnostics, Inc. (OTCBB: CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, and is the only New York-based manufacturer of rapid HIV/AIDS testing ...
A financially strapped Hauppauge-based manufacturer of diagnostic tests is being purchased by a French test maker for $17.2 million in cash, officials said. Chembio Diagnostics Inc. has signed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback